EP 2791681 A2 20141022 - METHOD FOR IDENTIFYING MARKER SEQUENCES FOR GYNAECOLOGICAL MALIGNANT TUMOURS
Title (en)
METHOD FOR IDENTIFYING MARKER SEQUENCES FOR GYNAECOLOGICAL MALIGNANT TUMOURS
Title (de)
VERFAHREN ZUR IDENTIFIZIERUNG VON MARKERSEQUENZEN FÜR GYNÄKOLOGISCHES MALIGNOM
Title (fr)
PROCÉDÉ D'IDENTIFICATION DE SÉQUENCES DE MARQUEURS POUR LE CANCER GYNÉCOLOGIQUE
Publication
Application
Priority
- EP 11194099 A 20111216
- EP 2012075778 W 20121217
- EP 12816261 A 20121217
Abstract (en)
[origin: EP2605017A1] Device comprises one or more different marker sequences consisting of a protein with a sequence of SEQ ID NOs: 979-1467 and/or its partial sequences and/or encoded by a sequence of SEQ ID NOs: 1-489, SEQ ID NOs: 490-978 and/or partial sequences of SEQ ID NOs. 1-978 on a carrier, where the above sequences are not defined. Independent claims are included for: (1) an assay or a protein biochip comprising the device; (2) a diagnostic (test kit) for the early detection and/or diagnosis of gynecological malignancy, prognosis and/or predicting the risk of metastasis in gynecological malignancy and the treatment monitoring and/or follow-up of gynecological malignancy comprising the device or an assay or a protein biochip and optionally further additives and auxiliaries; (3) early detection and diagnosis of gynecologic malignancy comprising applying the marker sequences on the carrier, followed by contacting with body fluid or tissue extract of a patient and detecting the interaction of body fluid or tissue extract with the marker sequences; (4) stratifying, preferably for risk stratification or therapy control of a patient with gynecological malignancy comprising determining the autoantibody profile of the patient using the marker sequences and optionally monitoring; (5) a target for the treatment and therapy of gynecological malignancy comprising the proteins; (6) identifying marker sequences for gynecological malignancy comprising providing the marker sequences on an array, identifying of marker sequence candidates for gynecological malignancy marker by comparative analysis of signals by contacting the marker sequences with body fluid or tissue extract of a patient with gynecological malignancy and body fluid or tissue extract of a patient without gynecological malignancy, characterizing the marker sequence candidates for gynecological malignancy using the protein biochip and selecting the marker sequence of candidates for gynecologic malignancy, which provide a different signal in patients with gynecological malignancies and patients without gynecological malignancy (marker sequences for gynecological malignancy); and (7) identifying and/or characterizing a substance (active ingredient) for gynecological malignancy comprising contacting the marker sequences consisting of the proteins and/or proteins encoded by a nucleic acid sequence with at least one substance to be examined and determining the binding. ACTIVITY : ACTIVITY -Cytostatic. MECHANISM OF ACTION : None given.
IPC 8 full level
G01N 33/574 (2006.01)
CPC (source: EP)
G01N 33/57411 (2013.01)
Citation (search report)
See references of WO 2013087929A2
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
EP 2605017 A1 20130619; EP 2791681 A2 20141022; WO 2013087929 A2 20130620; WO 2013087929 A3 20130808
DOCDB simple family (application)
EP 11194099 A 20111216; EP 12816261 A 20121217; EP 2012075778 W 20121217